New combo therapy for advanced melanoma using SX-682 with nivolumab and relatlimab
Official title: A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients
Funded at Syntrix Biosystems, INC. · NIH-11406776 · Data updated 2026-11-12
This grant tests a new combination treatment for advanced melanoma to see if it helps people whose cancer has progressed on prior immunotherapies.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Syntrix Biosystems, INC. NIH-funded |
| Lab location | 1 site (Auburn, United States) |
| Project start | September 14, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $406,500 |
| NIH project number | 1R44CA306688-01A1 |
| Project ID | NIH-11406776 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with advanced (unresectable or metastatic) melanoma who have progressed on prior anti-PD1 or combination immunotherapy and meet safety criteria.
✕Less likely to help
Patients whose tumors do not respond to CXCR1/2 pathway inhibition or who experience intolerable toxicity may not benefit.
What this research studies
Patients with advanced melanoma who have failed prior immune therapies may receive SX-682 together with nivolumab and relatlimab. The study will explore safety and potential signals of effectiveness in a phase 2 setting using existing checkpoint inhibitors plus the CXCR1/2 pathway blocker. Researchers will monitor tumor responses, progression-free survival, and overall survival while tracking immune-related side effects. The goal is to identify whether this combination can overcome resistance and extend meaningful benefits for patients who have limited options.
Why it matters
Potential benefit: If successful, patients could experience improved tumor control and longer survival with a new combination therapy.
How similar studies have gone: Early signals from similar combination approaches in melanoma suggest potential, but this exact combination is exploratory in nature.
Where this research is happening
-
Syntrix Biosystems, INC.
Auburn, United States Active
Researchers
- Principal investigator: Schuler, Aaron D — Syntrix Biosystems, INC.
- Study coordinator: Schuler, Aaron D
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.